Monte Rosa Therapeutics Inc
GLUE17.640USD
+1.160+7.04%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
1.09BMarket Cap
55.49P/E TTM
More Details of Monte Rosa Therapeutics Inc Company
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.
Monte Rosa Therapeutics Inc Info
Ticker SymbolGLUE
Company nameMonte Rosa Therapeutics Inc
IPO dateJun 24, 2021
CEOWarmuth (Markus)
Number of employees134
Security typeOrdinary Share
Fiscal year-endJun 24
Address321 Harrison Avenue
CityBOSTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02118
Phone16179492643
Websitehttps://www.monterosatx.com/
Ticker SymbolGLUE
IPO dateJun 24, 2021
CEOWarmuth (Markus)
Company Executives of Monte Rosa Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Sharon Townson, Ph.D.
Dr. Sharon Townson, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
36.00K
--
Ms. Jennifer Champoux
Ms. Jennifer Champoux
Chief Operating Officer
Chief Operating Officer
30.00K
--
Dr. Filip Janku, M.D., Ph.D.
Dr. Filip Janku, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
9.19K
-74.47%
Dr. Philip Nickson, J.D., Ph.D.
Dr. Philip Nickson, J.D., Ph.D.
Chief Business and Legal Officer
Chief Business and Legal Officer
--
-100.00%
Dr. Kimberly L. Blackwell, M.D.
Dr. Kimberly L. Blackwell, M.D.
Independent Director
Independent Director
--
--
Dr. Markus Warmuth, M.D.
Dr. Markus Warmuth, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Anthony M. Manning, Ph.D.
Dr. Anthony M. Manning, Ph.D.
Independent Director
Independent Director
--
--
Ms. Christine Siu
Ms. Christine Siu
Independent Director
Independent Director
--
--
Dr. Chandra P. Leo, M.D.
Dr. Chandra P. Leo, M.D.
Independent Director
Independent Director
--
--
Dr. Andrew N. (Drew) Schiff, M.D.
Dr. Andrew N. (Drew) Schiff, M.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Sharon Townson, Ph.D.
Dr. Sharon Townson, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
36.00K
--
Ms. Jennifer Champoux
Ms. Jennifer Champoux
Chief Operating Officer
Chief Operating Officer
30.00K
--
Dr. Filip Janku, M.D., Ph.D.
Dr. Filip Janku, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
9.19K
-74.47%
Dr. Philip Nickson, J.D., Ph.D.
Dr. Philip Nickson, J.D., Ph.D.
Chief Business and Legal Officer
Chief Business and Legal Officer
--
-100.00%
Dr. Kimberly L. Blackwell, M.D.
Dr. Kimberly L. Blackwell, M.D.
Independent Director
Independent Director
--
--
Dr. Markus Warmuth, M.D.
Dr. Markus Warmuth, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
New Enterprise Associates (NEA)
11.81%
BVF Partners L.P.
8.69%
Baker Bros. Advisors LP
7.55%
Versant Ventures
7.54%
Dimension Management, L.P.
7.31%
Other
57.10%
Shareholders
Shareholders
Proportion
New Enterprise Associates (NEA)
11.81%
BVF Partners L.P.
8.69%
Baker Bros. Advisors LP
7.55%
Versant Ventures
7.54%
Dimension Management, L.P.
7.31%
Other
57.10%
Shareholder Types
Shareholders
Proportion
Investment Advisor
34.60%
Venture Capital
28.98%
Hedge Fund
26.14%
Investment Advisor/Hedge Fund
13.75%
Research Firm
1.83%
Individual Investor
0.81%
Pension Fund
0.12%
Family Office
0.09%
Bank and Trust
0.09%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
233
66.43M
102.01%
+1.24M
2025Q2
232
62.74M
101.99%
-2.45M
2025Q1
235
60.82M
98.88%
-7.09M
2024Q4
220
61.73M
100.63%
-766.83K
2024Q3
200
57.64M
94.07%
-4.29M
2024Q2
191
55.42M
93.92%
+8.23M
2024Q1
185
49.41M
98.58%
+2.43M
2023Q4
187
49.83M
99.64%
+961.54K
2023Q3
187
51.89M
104.49%
+4.85M
2023Q2
202
40.69M
82.04%
-4.78M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
New Enterprise Associates (NEA)
7.69M
12.46%
--
--
Jun 30, 2025
BVF Partners L.P.
5.66M
9.16%
--
--
Jun 30, 2025
Baker Bros. Advisors LP
4.92M
7.96%
--
--
Jun 30, 2025
Versant Ventures
5.65M
9.15%
--
--
Jun 30, 2025
T. Rowe Price Associates, Inc.
6.23M
10.09%
-322.67K
-4.92%
Jun 30, 2025
Suvretta Capital Management, LLC
3.36M
5.44%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.36M
5.44%
+132.93K
+4.12%
Jun 30, 2025
The Vanguard Group, Inc.
3.14M
5.09%
+40.47K
+1.31%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
1.77%
Royce Quant Small-Cap Quality Value ETF
0.47%
iShares Micro-Cap ETF
0.12%
ProShares Ultra Nasdaq Biotechnology
0.12%
Avantis US Small Cap Equity ETF
0.08%
Invesco Nasdaq Biotechnology ETF
0.08%
iShares Russell 2000 Value ETF
0.05%
iShares Biotechnology ETF
0.05%
Invesco RAFI US 1500 Small-Mid ETF
0.04%
ProShares Hedge Replication ETF
0.03%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.77%
Royce Quant Small-Cap Quality Value ETF
Proportion0.47%
iShares Micro-Cap ETF
Proportion0.12%
ProShares Ultra Nasdaq Biotechnology
Proportion0.12%
Avantis US Small Cap Equity ETF
Proportion0.08%
Invesco Nasdaq Biotechnology ETF
Proportion0.08%
iShares Russell 2000 Value ETF
Proportion0.05%
iShares Biotechnology ETF
Proportion0.05%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.04%
ProShares Hedge Replication ETF
Proportion0.03%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Monte Rosa Therapeutics Inc?
The top five shareholders of Monte Rosa Therapeutics Inc are:
New Enterprise Associates (NEA) holds 7.69M shares, accounting for 12.46% of the total shares.
BVF Partners L.P. holds 5.66M shares, accounting for 9.16% of the total shares.
Baker Bros. Advisors LP holds 4.92M shares, accounting for 7.96% of the total shares.
Versant Ventures holds 5.65M shares, accounting for 9.15% of the total shares.
T. Rowe Price Associates, Inc. holds 6.23M shares, accounting for 10.09% of the total shares.
New Enterprise Associates (NEA) holds 7.69M shares, accounting for 12.46% of the total shares.
BVF Partners L.P. holds 5.66M shares, accounting for 9.16% of the total shares.
Baker Bros. Advisors LP holds 4.92M shares, accounting for 7.96% of the total shares.
Versant Ventures holds 5.65M shares, accounting for 9.15% of the total shares.
T. Rowe Price Associates, Inc. holds 6.23M shares, accounting for 10.09% of the total shares.
What are the top three shareholder types of Monte Rosa Therapeutics Inc?
The top three shareholder types of Monte Rosa Therapeutics Inc are:
New Enterprise Associates (NEA)
BVF Partners L.P.
Baker Bros. Advisors LP
New Enterprise Associates (NEA)
BVF Partners L.P.
Baker Bros. Advisors LP
How many institutions hold shares of Monte Rosa Therapeutics Inc (GLUE)?
As of 2025Q3, 233 institutions hold shares of Monte Rosa Therapeutics Inc, with a combined market value of approximately 66.43M, accounting for 102.01% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 0.02%.
What is the biggest source of revenue for Monte Rosa Therapeutics Inc?
In --, the -- business generated the highest revenue for Monte Rosa Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
